Skip to content

Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence

A Comparison Between Laparoscopic Burch Colposuspension and Transobturatory Tape (TOT) for the Treatment of Female Urinary Stress Incontinence

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00573703
Enrollment
0
Registered
2007-12-14
Start date
2007-09-30
Completion date
Unknown
Last updated
2013-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Keywords

Laparoscopic Burch colposuspension, Stress incontinence, Surgery, TOT, Treatment, Predominant or genuine stress urinary incontinence

Brief summary

Transobturatory tape (TOT) procedure is a minimally invasive approach to urinary stress incontinence owing to the category of the sling-adopting procedures. Its efficacy and safety, also in comparison with similar procedures have been demonstrated. The benefits of the sling- adopting procedures in comparison to laparoscopic Burch colposuspension, which has been considered as the gold standard treatment, have been showed. But these comparisons did not included the TOT procedure in the experimental arms. Based on this considerations the aim of this trial will be to compare TOT and laparoscopic Burch colposuspension in women with urinary stress incontinence.

Detailed description

Women with predominant and genuine stress urinary incontinence will be enrolled and randomized in two groups (groups A and B). Patients of group A will be treated with laparoscopic Burch colposuspension, whereas patients of group B will be treated with TOT procedure. All patients eligible will undergo baseline assessment consisting of anthropometric, clinical, hormonal, urodynamic, and ultrasonographic evaluations. During the study, the surgical outcomes, the clinical subjective and objective efficacy data, and the adverse experiences will be evaluated in each patient. Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less will be considered significant.

Interventions

Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.

PROCEDURETransobturator tape procedure

Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.

Sponsors

University Magna Graecia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Predominant or genuine stress urinary incontinence by self report,examination and test * Urethral hypermobility * Eligible for both surgical procedures * Ambulatory

Exclusion criteria

* Pregnancy * \<12 months post-partum * Systemic disease and/or drugs known to affect bladder function * Current chemotherapy or radiation therapy * Urethral diverticulum, augmentation cytoplasty, or artificial sphincter * Recent pelvic surgery * Severe genuine stress incontinence (loss of urine with minimal physical activity) with associated prolapse equal to or more than second degree * Previous pelvic or anti-incontinence surgery * History of severe abdominopelvic infections * Known extensive abdominopelvic adhesions * Detrusor instability and/or intrinsic sphincter dysfunction * Other gynaecologic pathologies (eg, fibroids, ovarian cysts) * BMI \>30

Design outcomes

Primary

MeasureTime frame
Objective/subjective symptoms improvements12 months

Secondary

MeasureTime frame
Postoperative complications rate12 months
Failure rate12 months
Intra-operative complication rateone day
Quality of life12 months
Sexual function12 months
Recurrence rate12 months

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026